# Lightpath Technologies Inc: Form 10-Q for the period ended Mar 31, 2016

- Company: [Lightpath Technologies Inc](/companies/lpth.md) (CIK 889971)
- Form: 10-Q
- Filed: 2016-05-05
- Accepted by EDGAR: May 5, 2016, 16:03 ET
- Period: 2016-03-31
- Accession: 0001387131-16-005275
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/889971/000138713116005275/lpth-10q_033116.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/889971/000138713116005275/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-01-01 to 2016-03-31 | $4.1m | us-gaap:SalesRevenueGoodsNet |
| Revenue | 9 months, 2015-07-01 to 2016-03-31 | $12.5m | us-gaap:SalesRevenueGoodsNet |
| Cost of revenue | 3 months, 2016-01-01 to 2016-03-31 | $1.9m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2015-07-01 to 2016-03-31 | $5.7m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2016-01-01 to 2016-03-31 | $2.2m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2015-07-01 to 2016-03-31 | $6.8m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2016-01-01 to 2016-03-31 | $1.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2015-07-01 to 2016-03-31 | $4.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-01-01 to 2016-03-31 | $213.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-07-01 to 2016-03-31 | $1.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2016-01-01 to 2016-03-31 | $127.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-07-01 to 2016-03-31 | $131.1k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-01-01 to 2016-03-31 | $775.8k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-07-01 to 2016-03-31 | $1.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-01-01 to 2016-03-31 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-07-01 to 2016-03-31 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-01-01 to 2016-03-31 | $0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-07-01 to 2016-03-31 | $0.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-01-01 to 2016-03-31 | 17,404,152 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-07-01 to 2016-03-31 | 16,843,880 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2015-07-01 to 2016-03-31 | $1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2015-07-01 to 2016-03-31 | $755.8k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-03-31 | $2.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-03-31 | $10.3m | us-gaap:AssetsCurrent |
| Total assets | at 2016-03-31 | $14.6m | us-gaap:Assets |
| Current liabilities | at 2016-03-31 | $2.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-03-31 | $4.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-03-31 | $10.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 55,866 characters.

*The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. All statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (the “Quarterly Report”), other than statements of historical facts, which address activities, events or developments that we expect or anticipate will or may occur in the future, including such things as future capital expenditures, growth, product development, sales, business strategy and other similar matters are forward-looking statements. These forward-looking statements are based largely on our current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond our control. Actual results could differ materially from the forward-looking statements set forth herein as a result of a number of factors, including, but not limited to, limited cash resources and the need for additional financing, our dependence on a few key customers, our ability to transition our business into new markets, our ability to increase sales and manage and control costs and other risks described in our reports on file with the SEC. In light of these risks and uncertainties, all of the forward-looking statements made herein are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by us will be realized. We undertake no obligation to update or revise any of the forward-looking statements contained herein.*

The discussions of our results as presented in this Quarterly Report include use of the non-GAAP term “gross margin.” Gross margin is determined by deducting the cost of sales from operating revenue. Cost of sales includes manufacturing direct and indirect labor, materials, services, fixed costs for rent, utilities and depreciation, and variable overhead. Gross margin should not be considered an alternative to operating income or net income, which are determined in accordance with GAAP. We believe that gross margin, although a non-GAAP financial measure is useful and meaningful to investors as a basis for making investment decisions. It provides investors with information that demonstrates our cost structure and provides funds for our total costs and expenses. We use gross margin in measuring the performance of our business and have historically analyzed and reported gross margin information publicly. Other companies may calculate gross margin in a different manner.

### Overview

### Historical:

We are in the business of manufacturing optical components and higher level assemblies including precision molded glass aspheric optics, proprietary high performance fiber optic collimators, GRADIUM glass lenses and other optical materials used to produce products that manipulate light. All the products we produce enable lasers and imaging devices to function more effectively.

In November 2005, we formed LPOI, a wholly-owned subsidiary, located in Jiading, People’s Republic of China. Over time, we transitioned a substantial portion of our manufacturing to LPOI, which until recently, operated as our primary manufacturing facility in China.

In December 2013, we formed LPOIZ, a wholly-owned subsidiary located in the New City district, of the Jiangsu province, of the People’s Republic of China. LPOIZ built out a 25,833 square foot manufacturing facility and production at LPOIZ’s new facility commenced in April 2014. We have now shifted our manufacturing operations from LPOI to LPOIZ, as LPOIZ’s facility provides a lower cost structure for production of larger volumes of optical components and assemblies, and further strengthens our partnerships within the Asia/Pacific region. The LPOI facility is now primarily used for sales and engineering functions.

### Product Groups and Markets:

During fiscal 2015, we started evaluating our business based on five product groups: low volume precision molded optics (“LVPMO”), high volume precision molded optics (“HVPMO”), specialty products, infrared products, and non-recurring engineering (“NRE”). Our LVPMO product group consists of precision molded optics with a sales price greater than $10 per lens and is usually sold in smaller lot quantities. Our HVPMO product group consists of precision molded optics with a sales price of less than $10 per lens and is usually sold in larger lot quantities. Our infrared product group is comprised of both molded lens and assemblies. Our specialty product group is comprised of value added products such as optical subsystems, assemblies, GRADIUM lenses, and isolators. Our NRE product group consists of those products we develop pursuant to product development agreements we enter into with customers. Typically, customers approach us and request that we develop new products or applications for our existing products to fit their particular needs or specifications. The timing and extent of any such product development is outside of our control.

We currently serve the following major markets: distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense. Within our product groups, we have various applications that serve these major markets. For example, our HVPMO lenses are typically used in industrial tools, especially in China. Our HVPMO and LVPMO lenses are also used in applications for the telecommunications market, such as cloud computing, video distribution via digital technology, wireless broadband, and machine to machine connection, and, the laser market, such as laser tools, scientific and bench top lasers, and bar code scanners. Our infrared products can also be used in various applications within our major markets. Currently, sales of our infrared products are primarily for customers in the industrial market that use thermal imaging cameras. Our infrared products can also be used for gas sensing devices, spectrometers, night vision systems, automotive driver systems, thermal weapon gun sights, and infrared counter measure systems, among others. Within the larger overall markets, which are estimated to be in the multi-billions of dollars, we believe there is a market of approximately $800 million for our current products and capabilities. We continue to believe our products will provide significant growth opportunities over the next several years and, therefore, we will continue to target specific applications in each of these major markets. Our strategy is to leverage our technology, know-how, established low cost manufacturing capability and partnerships to grow our business.

### How we operate:

We have continuing sales of two basic types: occasional sales via ad-hoc purchase orders of mostly standard product configurations (our “turns” business) and the more challenging and potentially more rewarding business of customer product development. In this latter type of business we work with customers to help them determine optical specifications and even create certain optical designs for them, including complex multi-component designs that we call “engineered assemblies”. This is followed by “sampling” small numbers of the product for the customers’ test and evaluation. Thereafter, should a customer conclude that our specification or design is the best solution to their product need; we negotiate and “win” a contract (sometimes called a “design win”) – whether of a “blanket purchase order” type or a supply agreement. The strategy is to create an annuity revenue stream that makes the best use of our production capacity as compared to the turns business, which is unpredictable and uneven. This annuity revenue stream can also generate low-cost, high-volume type orders. A key business objective is to convert as much of our business to the design win and annuity model as is possible. We face several challenges in doing so:

- Maintaining an optical design and new product sampling capability, including a high-quality and responsive optical design engineering staff;
- The fact that as our customers take products of this nature into higher volume, commercial production (for example, in the case of molded optics, this may be volumes over one million pieces per year) they begin to work seriously to reduce costs – which often leads them to turn to larger or overseas producers, even if sacrificing quality; and
- Our small business mass means that we can only offer a moderate amount of total productive capacity before we reach financial constraints imposed by the need to make additional capital expenditures – in other words, because of our limited cash resources and cash flow, we may not be able to service every opportunity that presents itself in our markets without arranging for such additional capital expenditures.

Despite these challenges to winning more “annuity” business, we nevertheless believe we can be successful in procuring this business because of our unique capabilities in optical design engineering that we make available on the merchant market, a market that we believe is underserved in this area of service offering. Additionally, we believe that we offer value to some customers as a source of supply in the United States should they be unwilling to commit their entire source of supply of a critical component to foreign merchant production sources. We also continue to have the proprietary GRADIUM lens glass technology to offer to certain laser markets.

### Our key indicators:

Usually on a weekly basis, management reviews a number of performance indicators. Some of these indicators are qualitative and others are quantitative. These indicators change from time to time as the opportunities and challenges in the business change. They are mostly non-financial indicators such as units of shippable output by product line, production yield rates by major product line and the output and yield data from significant intermediary manufacturing processes that support the production of the finished shippable product. These indicators can be used to calculate such other related indicators as fully yielded unit production per-shift, which varies by the particular product and our state of automation in production of that product at any given time. Higher unit production per shift means lower unit cost and therefore improved margins or improved ability to compete where desirable for price sensitive customer applications. The data from these reports is used to determine tactical operating actions and changes. We believe that our non-financial production indicators, such as those noted, are proprietary information.

Financial indicators that are usually reviewed at the same time include the major elements of the micro-level business cycle:

- sales backlog;
- revenue dollars and units by product group;
- inventory levels;
- accounts receivable levels and quality; and
- other key indicators.

These indicators are similarly used to determine tactical operating actions and changes and are discussed in more detail below.

### Sales Backlog:

Sales growth has been and continues to be our best indicator of success. Our best view into the efficacy of our sales efforts is in our “order book.” Our order book equates to sales “backlog.” It has a quantitative and a qualitative aspect: quantitatively, our backlog’s prospective dollar value and qualitatively, what percent of the backlog is scheduled by the customer for date-certain delivery. We define our “12-month backlog” as that which is requested by the customer for delivery within one year and which is reasonably likely to remain in the backlog and be converted into revenues. This includes customer purchase orders and may include amounts under supply contracts if they meet the aforementioned criteria. Generally, a higher 12-month backlog is better for us.

Our 12-month backlog at March 31, 2016 was approximately $6.97 million compared to $6.49 million as of June 30, 2015. Backlog growth rates for the last five fiscal quarters are:

| Quarter | Backlog ($ 000) | Change From Prior Year End | Change From Prior Quarter End |
| --- | ---: | ---: | ---: |
| **Q3 2015** | $6,153 | 44% | 10% |
| **Q4 2015** | $6,493 | 52% | 6% |
| **Q1 2016** | $5,064 | -22% | -22% |
| **Q2 2016** | $6,424 | -1% | 27% |
| **Q3 2016** | $6,969 | 7% | 8% |

Our order intake softened in the first quarter of fiscal 2016 due to the delay and certain requirement changes for some larger projects we quoted within our specialty products group, which negatively affected our 12-month backlog during the first quarter of 2016. However, our 12-month backlog has recovered in the subsequent two quarters with an uptick in order intakes, many of which were derived from the medical and telecommunications sectors. We booked approximately $5.1 million in new orders in the second quarter of fiscal 2016 and approximately $5.2 million in the third quarter of fiscal 2016.

We have diversified our business by developing new applications for our products in markets such as digital imaging, laser tools, telecommunications, digital projectors, industrial equipment, weapon sights, medical instruments and green lasers. Examples of these new applications include: 2D scanning, fiber laser delivery systems, disposable medical instruments, and infrared sensor applications. Based on recent quote activity, we expect to show increases in revenue of our LVPMOs, HVPMOs, specialty products and infrared products for the remainder of fiscal 2016.

### Revenue Dollars and Units by Product Group:

The following table sets forth revenue dollars and units for our five product groups for the three and nine month periods ended March 31, 2016 and 2015:

*(unaudited)*

*(unaudited)*

|  |  | Three months ended March 31, 2016 | 2015 | QTR % Change | Nine months ended March 31, 2016 | 2015 | Year-to-date % Change |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | LVPMO | 1,786,187 | 1,545,555 | 16% | 5,255,641 | 4,802,301 | 9% |
|  | HVPMO | 923,896 | 564,969 | 64% | 2,607,496 | 1,681,871 | 55% |
|  | Infrared Products | 386,959 | 303,510 | 27% | 1,111,901 | 776,361 | 43% |
|  | Speciality Products | 838,984 | 758,720 | 11% | 3,052,947 | 1,770,241 | 72% |
|  | NRE | 175,947 | 26,000 | 577% | 510,649 | 124,247 | 311% |
|  | Total sales, net | 4,111,973 | 3,198,754 | 29% | 12,538,634 | 9,155,022 | 37% |
| Units | LVPMO | 79,075 | 61,221 | 29% | 218,087 | 201,335 | 8% |
|  | HVPMO | 312,657 | 233,661 | 34% | 1,059,849 | 913,309 | 16% |
|  | Infrared Products | 8,539 | 5,628 | 52% | 19,744 | 13,535 | 46% |
|  | Speciality Products | 10,027 | 49,327 | -80% | 93,011 | 126,710 | -27% |
|  | NRE | 412 | 2 | 20500% | 454 | 66 | 588% |
|  |  | 410,710 | 349,839 | 17% | 1,391,145 | 1,254,955 | 11% |

Overall, our global diversification strategies have resulted in revenue increasing by 29% in the third quarter of fiscal 2016, as compared to the prior year period, and by 27% in the first nine months of fiscal 2016, as compared to the prior year period, with growth in revenue in all of our products groups.

The HVPMO product group benefitted from the strength in the telecommunications sector as the demand for increased bandwidth continues. During the third quarter of fiscal 2016, sales of HVPMO lens units increased by 34%, and the average selling price increased by 22%, both as compared to the prior period, which produced a 64% increase in HVPMO revenue as compared to the prior year period. During the first nine months of fiscal 2016, sales of HVPMO lens units increased by 16% and the average selling price increased by 32%, both as compared to the prior year period, which produced a 53% increase in HVPMO revenue during the first nine months of fiscal 2016, as compared to the prior year period, with growth in sales to our distributors and to customers in the telecommunications sector. Historically, revenue from our HVPMO product group has been derived from the industrial tool market in China, which had experienced six years of declining growth.

Our unit shipment volume in LVPMO lenses increased by 29% in the third quarter of fiscal 2016, as compared to the same period of the prior fiscal year, which resulted in a 16% increase in revenue in the third quarter of fiscal 2016, compared to the same period of the prior fiscal year. This increase is attributed to growth in sales to customers in the telecommunications, defense, industrial, and medical sectors. For the first nine months of fiscal 2016, our unit shipment volume in LVPMO lenses increased by 9%, and our average selling price increased 2%, both as compared to the same period of the prior fiscal year, which resulted in an increase in revenue of 53%, in the first nine months of fiscal 2016, as compared to the same period of the prior fiscal year.

We also had growth in the infrared product group. Our infrared product revenue increased by 27% in the third quarter of fiscal 2016, as compared to the prior year period, and increased by 43% in the first nine months of fiscal 2016, as compared to the prior year period. The increases in revenue are primarily derived from sales to customers in the industrial market.

Sales in our NRE products group increased significantly by 577% in the third quarter of fiscal 2016, as compared to the prior year period, and by 311% in the first nine months of fiscal 2016, as compared to the prior year period, due to projects for customers in the infrared, medical device and industrial markets. NRE revenue is project based and timing of any such projects is wholly dependent on our customers and their project activity. Accordingly, management does not include NRE in its projections or forecasts for purposes of developing its operating plan and budget.

We are also pleased with the growth in revenues for the specialty product group. In the third quarter of fiscal 2016, our specialty product revenue increased by 11%, as compared to the prior year period. In the first nine months of fiscal 2016, our specialty product revenue increased by 72%, as compared to the prior year period. The increases in revenue are primarily derived from sales to customers in the industrial market for our collimators and assemblies. Approximately $272,000 of the specialty group sales from the third quarter of fiscal 2016, compared to $294,000 in the third quarter of fiscal 2015, and approximately $1,080,000 of the specialty group sales from the first nine months of fiscal 2016, compared to $430,000 for the first nine months of fiscal 2015, were due to fiber collimator assemblies sold to the Customer pursuant to the License Agreement.

### Inventory Levels:

We manage our inventory levels to minimize investment in working capital but still have the flexibility to meet customer demand to a reasonable degree. Management constantly reviews our inventory amounts, and, if such amount substantially increases or decreases, management will further investigate the causes of any such fluctuations. While the amount and mix of inventory is an important factor, including adequate safety stocks of long lead-time materials, another important aggregate measure of inventory in all phases of production is the quarter’s ending inventory expressed as a number of days worth of the quarter’s cost of sales, also known as “days cost of sales in inventory,” or “DCSI.” It is calculated by dividing the quarter’s ending inventory by the quarter’s cost of goods sold, multiplied by 365 and divided by 4. Generally, a lower DCSI measure equates to a lesser investment in inventory and therefore more efficient use of capital. During the quarters ended March 31, 2016 and 2015, our DCSI was 178 and 195 respectively, compared to an average DCSI of 165 for the year ended June 30, 2015. The increase in DCSI from the previous fiscal year end is due to higher levels of finished inventory to support our 12-month backlog and our sales forecast, as well as an increase in revenues.

### Accounts Receivable Levels and Quality:

Similarly, we manage our accounts receivable to minimize investment in working capital. We measure the quality of receivables by the proportions of the total that are at various increments past due from our normally extended terms, which are generally 30 days. Management closely manages outstanding accounts receivables and promptly takes action once amounts are outstanding more than 30 days. An important aggregate measure of accounts receivable is the quarter’s ending balance of net accounts receivable expressed as a number of days’ worth of the quarter’s net revenues, also known as “days sales outstanding,” or “DSO.” It is calculated by dividing the quarter’s ending net accounts receivable by the quarter’s net revenues, multiplied by 365 and divided by 4. Generally, a lower DSO measure equates to a lesser investment in accounts receivable, and therefore, more efficient use of capital. For the quarters ended March 31, 2016 and 2015, our DSO was 67. For the year ended June 30, 2015, our average DSO was 67. We strive to have a DSO no higher than 65.

### Other Key Indicators:

Other key indicators include various operating metrics, some of which are qualitative and others are quantitative. These indicators change from time to time as the opportunities and challenges in the business change. They are mostly non-financial indicators such as on time delivery trends, units of shippable output by major product line, production yield rates by major product line, and the output and yield data from significant intermediary manufacturing processes that support the production of the finished shippable product. These indicators can be used to calculate such other related indicators as fully-yielded unit production per-shift, which varies by the particular product and our state of automation in production of that product at any given time. Higher unit production per shift means lower unit cost, and, therefore, improved margins or improved ability to compete where desirable for price sensitive customer applications. The data from these reports is used to determine tactical operating actions and changes. Management also assesses business performance and makes business decisions regarding our operations using certain non-GAAP measures. These non-GAAP measures are described in more detail below under the heading “Non-GAAP Financial Measures.”

Results of Operations

### Fiscal Third Quarter: Three months ended March 31, 2016 compared to the three months ended March 31, 2015

### Revenues:

For the quarter ended March 31, 2016, our total revenues increased by 29% to $4.11 million, compared to $3.20 million for the quarter ended March 31, 2015. This increase was primarily attributable to a 16% increase in sales of LVPMOs and an increase of 64% in sales of our HVPMOs.

Unit shipment volume in HVPMO lenses increased by 34% in the third quarter of fiscal 2016 as compared to the same period of the prior fiscal year, primarily as a result of the strength in the telecommunications sector as the demand for bandwidth continues. Historically, revenue from our HVPMO product group is derived from sales to the industrial tool market in China, which has been impacted by six years of a slowing Chinese economy, but is showing signs of improvement. We expect the Chinese industrial tool market to continue its recovery during the fourth quarter of fiscal 2016 as a result of the stimulus by the Chinese government to promote construction, which we believe will increase sales of our HVPMO lenses.

Our unit shipment volume of LVPMO lenses increased 29% in the third quarter of fiscal 2016 compared to the same period of the prior fiscal year, which resulted in an increase in revenue of 16% in the third quarter of fiscal 2016, compared to the same period in the prior year. This increase is attributed to growth in sales to customers in the telecommunications, defense, industrial, and medical sectors. The average selling price decreased by 10%, compared to the same period in the prior year.

### Cost of Sales:

Our gross margin percentage in the third quarter of fiscal 2016 was 54% compared to 50% for the third quarter of fiscal 2015. The improvement in gross margin is primarily attributed to increased revenues with a favorable product mix resulting in higher sales prices, leverage of our sales volume against our manufacturing overhead costs, the realization of the full benefit of LPOIZ’s Zhenjiang facility lower cost structure and better yields for infrared products. Total manufacturing costs were approximately $1.89 million for the third quarter, an increase of approximately $289,000 as compared to the same period of the prior fiscal year.

### Selling, General and Administrative:

During the third quarter of fiscal 2016, selling, general and administrative (“SG&A”) costs were approximately $1.81 million, compared to $1.14 million in the third quarter of fiscal 2015, an increase of approximately $667,000. The increase was primarily due to: (i) a $151,000 accrual for fiscal 2016 management bonuses given the strong performance during the first, second and third quarters of fiscal 2016, (ii) a $109,000 reclassification of wages from new product development as a result of the transition to a technical sales process, which we announced in February 2015 as part of our organizational optimization plan, (iii) a $100,000 payment for early termination of a sales agreement, (iv) a $67,000 increase for fees related to our annual stockholders’ meeting and related proxy solicitations, (v) a $66,000 increase in legal expenses relating to the annual meeting and other growth initiavives, (vi) a $60,000 increase in costs for trade shows and travel and (vii) a $114,000 increase in other expenses. We expect future SG&A costs to decrease slightly during the fourth quarter of fiscal 2016, and return to more normal levels.

### New Product Development:

New product development costs were approximately $165,000 in the third quarter of fiscal 2016, a decrease of $84,000 as compared to the third quarter of fiscal 2015. This decrease was primarily due to a decrease in wages as a result of the reclassification to SG&A in connection with our transition to a technical sales process, offset by an increase in materials used for engineering projects. We anticipate that these expenses will remain at current levels for the remainder of fiscal year 2016.

### Other Income (Expense):

Interest expense was approximately $8,000 in the third quarter of fiscal 2016 as compared to $3,000 in the third quarter of fiscal 2015. Interest expense resulted from amortization of debt costs related to our Invoiced Based Line with Avidbank and payments on capital leases.

In the third quarter of fiscal 2016, we recognized non-cash income of approximately $662,000 related to the change in the fair value of warrant liability in connection with our June 2012 Warrants. We recognized expense of approximately $106,000 in the same period last year. This fair value will be re-measured each reporting period throughout the remaining contractual term of the warrants, or until exercised.

Other income, net was approximately $36,000 in the third quarter of fiscal 2016 compared to expense of approximately $8,000 in the third quarter of fiscal 2015. We had foreign exchange gains in the third quarter of fiscal 2016 due to the recent changes in the value of the Chinese yuan in the amount of approximately $34,000, which had no impact on basic and diluted earnings per share. This compares to a foreign exchange loss of $8,000 in the same period of the prior fiscal period.

### Income taxes:

Income tax expense was approximately $127,000 in the third quarter of fiscal 2016, an increase of $126,000 from the third quarter of fiscal 2015. This increase was primarily attributable to income taxes associated with our Chinese operations. All previous Chinese tax operating loss carry forwards are now depleted, there are still substantial tax operating loss carry forwards remaining in the United States. We anticipate that these expenses will remain at current levels for the remainder of fiscal year 2016.

### Net Income:

Net income was approximately $776,000, or $0.05 basic and $0.04 diluted earnings per share, during the third quarter of fiscal 2016, compared with the third quarter of fiscal 2015, in which we reported net income of approximately $90,000, or $0.01 basic and diluted earnings per share. The approximately $686,000 increase in net income in the third quarter of fiscal 2016, as compated to the prior year period, is as a result of an approximately $767,000 increase in non-cash expense in the change in the fair value of warrant liability for the June 2012 Warrants.

Weighted-average shares outstanding (basic) was 15,530,574 in the third quarter of fiscal 2016 compared to 15,028,231 in the third quarter of fiscal 2015. The increase in weighted-average shares outstanding was primarily due to the issuance of shares of Class A common stock related to shares issued under the 2014 ESPP and exercises of stock options and warrants.

### Fiscal First Nine Months: Nine months ended March 31, 2016 compared to the nine months ended March 31, 2015

### Revenues:

For the nine months ended March 31, 2016, our total revenues increased by 37% to $12.54 million, compared to $9.16 million for the nine months ended March 31, 2015. This increase was due to increases in sales across all of our product groups. Specifically we had a 311% increase in sales of our NRE products, a 72% increase in sales of our specialty products, a 43% increase in sales of our infrared products, and a 53% increase in sales of HVPMO products and a 10% increase in sales of LVPMO products. Due to recent bookings and quoting trends, we expect increases in revenue for our LVPMOs, HVPMOs, specialty products and infrared products during the fourth quarter of fiscal 2016.

Unit shipment volume in HVPMO lenses increased by 16% in the first nine months of fiscal 2016 compared to the same period of the prior fiscal year due to the strength in the telecommunications sector as the demand for increased bandwidth continues. Historically, revenue from our HVPMO product group is derived from sales for the industrial tool market in China, which has been impacted by six years of a slowing Chinese economy, but is showing signs of improvement. We expect the Chinese industrial tool market to continue to recover during the remainder of fiscal 2016 as a result of the stimulus by the Chinese government to promote construction takes effect.

During the first nine months of fiscal 2016, our unit shipment volume of LVPMO lenses increased by 9%, and the average selling price increased by 2%, both as compared to the same period of the prior fiscal period, which resulted in a 10% increase in revenue as compared to the same period in the prior year. The increase in the average selling price of our LVPMO is primarily attributed to our entry into new applications in the medical instruments and fiber laser delivery systems markets.

### Cost of Sales:

Our gross margin percentage in the first nine months of fiscal 2016 was 55% compared to 42% for the first nine months of fiscal 2015. The improvement in gross margin is primarily attributed to favorable product mix resulting in higher sales prices, leverage of the sales volume against our manufacturing overhead costs, the realization of the full benefit of LPOIZ’s Zhenjiang facility and improved yields of our infrared products. Total manufacturing costs of approximately $5.70 million increased by approximately $396,000 in the first nine months of fiscal 2016 compared to the same period of the prior fiscal year. The increase was primarily due to direct costs attributable to the increased revenues.

### Selling, General and Administrative:

During the first nine months of fiscal 2016, SG&A costs were approximately $4.82 million, compared to $3.61 million in the first nine months of fiscal 2015, an increase of approximately $1.21 million. The increase was primarily due (i) a $491,000 accrual for fiscal 2016 management bonuses given the strong performance during the first, second and third quarters of fiscal 2016, (ii) a $394,000 reclassification of wages from new product development as a result of the transition to a technical sales process, which we announced in February 2015 as part of our organizational optimization plan, (iii) a $100,000 payment for early termination of a sales agreement, (iv) a $63,000 increase for fees related to our annual stockholders’ meeting and proxy solicitations, (v) a $57,000 increase in stock compensation expense and (vi) a $105,000 increase in other expenses.

### New Product Development:

New product development costs were approximately $481,000 in the first nine months of fiscal 2016, a decrease of $462,000 from the first nine months of fiscal 2015. This decrease was primarily due to a decrease of $418,000 in wages due to the reclassification to SG&A in connection with our transition to a technical sales process, a decrease of $28,000 in travel costs and a decrease of $17,000 in outside services for research and development projects. We anticipate that these expenses will remain at current levels for the remainder of fiscal 2016.

### Other Income (Expense):

Interest expense was approximately $30,000 in the first nine months of fiscal 2016 as compared to $26,000 in the first nine months of fiscal 2015. Interest expense resulted from amortization of debt costs related to our Invoiced Based Line with Avidbank and payments on capital leases.

In the first nine months of fiscal 2016, we recognized non-cash expense of approximately $25,000 related to the change in the fair value of warrant liability in connection with our June 2012 Warrants. We recognized income of approximately $375,000 in the same period last year. The fair value of the June 2012 Warrants outstanding will be re-measured each reporting period throughout the remaining contractual term of the warrants, or until exercised.

Other expense, net was approximately $217,000 in the first nine months of fiscal 2016 compared to income of approximately $12,000 in the first nine months of fiscal 2015. We were also impacted by foreign exchange losses in the first nine months of fiscal 2016 due to the recent de-valuing of the Chinese yuan in the amount of approximately $221,000, which had a ($0.01) impact on basic and diluted earnings per share. This compares to a foreign exchange loss of $2,000 in the same period of the prior fiscal period.

### Income taxes:

Income tax expense was approximately $131,000 in the first nine months of fiscal 2016, an increase of $129,000 from the first nine months of fiscal 2015. This increase was primarily attributable to income taxes associated with our Chinese operations. All previous Chinese tax operating loss carry forwards are now depleted, there are still substantial tax operating loss carry forwards remaining in the United States. We anticipate that these expenses will remain at current levels for the remainder of fiscal year 2016.

### Net Income (Loss):

Net income was approximately $1.08 million, or $0.07 basic and $0.06 diluted earnings per share, during the first nine months of fiscal 2016, compared with the first nine months of fiscal 2015, in which we reported a net loss of approximately $348,000, or $0.02 basic and diluted loss per share. The approximately $1.43 million increase in net income resulted from an increase in gross margin of approximately $2.99 million, offset by an approximately $793,000 increase in total costs and expenses, an approximately $401,000 expense recognized as a result of the change in the fair value of warrant liability and an increase of approximately $230,000 in foreign exchange losses due to changes in the Chinese exchange rate.

Weighted-average shares outstanding (basic) was 15,339,337 in the first nine months of fiscal 2016 compared to 14,537,727 in the first nine months of fiscal 2015. The increase in weighted-average shares outstanding was primarily due to the issuance of shares of common stock related to shares issued under the 2014 ESPP, our private placement in January 2015 with Pudong Investment and shares issued with the exercise of stock options and warrants.

### Liquidity and Capital Resources

At March 31, 2016, we had working capital of approximately $7.59 million and total cash and cash equivalents of approximately $2.86 million, of which approximately $1.28 million of total cash and cash equivalents were held by our foreign subsidiaries.

Cash and cash equivalents held by our foreign subsidiaries were generated in China as a result of foreign earnings. Before any funds can be repatriated, the retained earnings in China must equal at least 150% of the registered capital. As of March 31, 2016, we have retained earnings of $2.12 million and we need to have $11.3 million before repatriation will be allowed. We currently do not anticipate that we will need funds generated from foreign operations to fund our domestic operations. In the event that funds from foreign operations are needed to fund operations in the United States, and if United States taxes have not been previously provided on the related earnings, we would provide for and pay additional United States taxes at the time we change our intention with regard to the reinvestment of those earnings.

We generally rely on cash from operations and equity and debt offerings, to the extent available, to satisfy our liquidity needs.

On December 23, 2014, we entered into the Amended LSA with Avidbank for the Invoice Based Line. Pursuant to the Amended LSA, Avidbank will, in its discretion, make loan advances to us up to a maximum aggregate principal amount outstanding not to exceed the lesser of (i) One Million Dollars ($1,000,000) or (ii) eighty percent (80%) (the “Maximum Advance Rate”) of the aggregate balance of our eligible accounts receivable, as determined by Avidbank in accordance with the Amended LSA. Avidbank may, in its discretion, elect to not make a requested advance, determine that certain accounts are not eligible accounts, change the Maximum Advance Rate or apply a lower advance rate to particular accounts and terminate the Amended LSA. Our obligations under the Amended LSA are secured by a first priority security interest (subject to permitted liens) in cash, U.S. inventory and accounts receivable.

On December 23, 2015, we executed the First Amendment to the Amended LSA to extend the term to December 23, 2016. Amounts borrowed under the Amended LSA may be repaid and re-borrowed at any time prior to December 23, 2016, at which time all amounts shall be immediately due and payable. The amount outstanding on the Amended LSA was $0 as of March 31, 2016. For additional information, see Note 11, Loan Payable, to the Notes to the Financial Statements to this quarterly report on Form 10-Q.

Management developed an operating plan for fiscal 2016 and believes we have adequate financial resources to achieve this plan and to sustain our current operations in the coming year. We have established milestones that will be tracked to ensure that as funds are expended we are achieving results before additional funds are committed. The fiscal 2017 operating plan and related financial projections we have developed anticipate sales growth primarily from precision molded optics, with the emphasis on HVPMO applications, specialty products, and infrared products. We also expect to be better positioned to accelerate our revenue growth and profitability as a result of our transition to a technical sales process that leverages the success of our existing demand-creation model. The technical sales process will further enhance our incremental organic growth position for our core aspheric lens business, prime our operations for the anticipated high growth of our new infrared products, and allow for the integration of strategic acquisitions. We have also benefited from a substantial increase in revenue generating opportunities and broader market applications as a result of our investments in technologies that decreased our lens production costs and expanded our production capacity. We believe we can further improve upon our track record of growth – and do so far more profitably.

Our future capital requirements will depend on many factors including a decline in revenue or a lack of anticipated sales growth, increased material costs, increased labor costs, planned production efficiency improvements not being realized, increases in property, casualty, benefit and liability insurance premiums, and increases in other discretionary spending, particularly sales and marketing related. We will also continue efforts to keep costs under control as we seek renewed sales growth. Our efforts continue to be directed toward maintaining positive cash flow and profitability. If our efforts are not successful, we will need to raise additional capital. Should capital not be available to us at reasonable terms, other actions may become necessary in addition to cost control measures and continued efforts to increase sales. These actions may include exploring strategic options for the sale of the Company, the sale of certain product lines, the creation of joint ventures or strategic alliances under which we will pursue business opportunities, the creation of licensing arrangements with respect to our technology, or other alternatives.

#### Cash Flows – Financings:

Net cash provided by financing activities was approximately $272,000 in the first nine months of fiscal 2016 compared to net cash provided of approximately $954,000 in the first nine months of fiscal 2015, a decrease of approximately $682,000. The decrease was primarily attributed to $1.12 million received from the sale of Class A common stock to Pudong Investment in the prior period, offset by $391,000 of proceeds for warrant exercises in the current period.

#### Cash Flows – Operating and Investing:

Cash flow provided by operations was approximately $1.24 million for the nine months ended March 31, 2016, an increase of approximately $1.90 million as compared to the first nine months of fiscal 2015. Our fiscal 20176 operating plan and related financial projections anticipate improvement in our cash flows provided by operations in future years due to sales growth and continued margin improvements based on production efficiencies and reductions in product costs, offset by marginal increases in selling, administrative, and new product development expenditures. For example, we expect lower operating costs as a result of moving the majority of our manufacturing operations to LPOIZ’s Zhenjiang facility, and lower coating costs due to larger unit volumes and due to our ability to coat the lenses in house rather than out-sourcing this service. We are in the process of adding equipment at LPOIZ’s Zhenjiang facility in order to coat our infrared lenses in-house.

During the first nine months of fiscal 2016, we expended approximately $756,000 for capital equipment as compared to $516,000 during the first nine months of fiscal 2015. The majority of our capital expenditures during fiscal 2016 and fiscal 2015 were related to the purchase of equipment used to enhance or expand our production capacity, tooling for our precision molded products, and equipment and facility improvements for LPOIZ’s new facility in Zhenjiang. Overall, we anticipate an increase in capital expenditures during fiscal 2016; however, the total amount expended during the remainder of fiscal 2016 will depend on opportunities and circumstances.

#### License Agreement:

On April 28, 2015, we entered into a License Agreement with a Customer, whereby we granted an irrevocable license of certain technology to be used by a Customer to manufacture fiber collimator assemblies. We will provide process work instructions, training and inventory. Pursuant to the License Agreement, we received $200,000 in fees in consideration of our disclosure of the technology and the grant of a license to the customer to use the technology to manufacture specific fiber collimator assemblies used by the Customer. The license fees were paid in two installments. The first installment of $100,000 was received in May 2015 and the second installment of $100,000 was received in August 2015. The transaction was accounted for under the guidance of ASC 605-10, Revenue Recognition and was recognized over the ninety-day training period which was completed in August 2015. Pursuant to the License Agreement, the Customer also agreed to order and purchase from us a certain number of fiber collimator assemblies. We recognized approximately $124,000 of revenue in fiscal 2015 and $71,000 in the first nine months of fiscal 2016, with expenses of $18,000 in fiscal 2015 and $11,000 in the first nine months of fiscal 2016. The total costs associated with this License Agreement are estimated to be approximately $33,000.

### Non-GAAP Financial Measures

We report our historical results in accordance with GAAP; however, our management also assesses business performance and makes business decisions regarding our operations using certain non-GAAP measures. We believe these non-GAAP financial measures provide useful information to management and investors that is supplementary to our financial condition and results of operations computed in accordance with GAAP; however, we acknowledge that our non-GAAP financial measures have a number of limitations. As such, you should not view these disclosures as a substitute for results determined in accordance with GAAP, and they are not necessarily comparable to non-GAAP measures that other companies use.

### Adjusted Net Income (Loss):

We calculate adjusted net income (loss) by excluding the change in the fair value of the June 2012 Warrants from net income (loss). The fair value of the June 2012 Warrants is re-measured each reporting period until the warrants are exercised or expire. Each reporting period, the change in the fair value of the June 2012 Warrants is either recognized as non-cash expense or non-cash income. The change in the fair value of the June 2012 Warrants is not impacted by our actual operations but is instead strongly tied to the change in the market value of our common stock. Management uses adjusted net income (loss) to evaluate our operating performance and for planning and forecasting future business operations. We believe the use of adjusted net income (loss) may be useful to investors as one means of evaluating our operational performance. The following table reconciles adjusted net income (loss) to net income (loss) for the three and nine months ended March 31, 2016 and 2015:

|  | Three months ended: March 31, 2016 | March 31, 2015 | Nine months ended: March 31, 2016 | March 31, 2015 |
| --- | ---: | ---: | ---: | ---: |
| Net income (loss) | $775,758 | $89,791 | $1,083,148 | $(348,046) |
| Change in fair value of warrant liability | (661,854) | 105,518 | 25,211 | (375,308) |
| Adjusted net income (loss) | $113,904 | $195,309 | $1,108,359 | $(723,354) |

29

Our adjusted net income for the three months ended March 31, 2016 was approximately $114,000, as compared to adjusted net income of approximately $195,000 for the three months ended March 31, 2015. The difference in adjusted net income between the periods was principally caused by higher gross margin due to higher revenues offset by higher total costs and expenses being recognized in the third quarter of fiscal 2016 versus in the third quarter of fiscal 2015. We also recognized non-cash income as a result of the change in the fair value of the June 2012 Warrant liability during the third quarter of fiscal 2016, as compared to non-cash expense during the prior year period. The market value per share of common stock decreased by 29% during the third quarter of fiscal 2016 as compared to the third quarter of fiscal 2015, which aided in the recognition of non-cash income as compared to non-cash expense recorded for the same period in fiscal 2015.

Our adjusted net income for the nine months ended March 31, 2016 was approximately $1.11 million, as compared to adjusted net loss of approximately $723,000 for the nine months ended March 31, 2015. The difference in adjusted net income (loss) between the periods was principally caused by net income being recognized in the first nine months of fiscal 2016 versus a net loss in the first nine months of fiscal 2015. We also recognized non-cash income as a result of the change in the fair value of the June 2012 Warrant liability during the first nine months ended March 31, 2016, as compared to non-cash expense during the prior year period. The market value per share of common stock increased by 15% during the first none months of fiscal 2016 as compared to the first nine months of fiscal 2015, which aided in the recognition of non-cash expense as compared to non-cash income recorded for the same period in fiscal 2015.

### EBITDA and Adjusted EBITDA:

EBITDA and adjusted EBITDA are non-GAAP financial measures used by management, lenders, and certain investors as a supplemental measure in the evaluation of some aspects of a corporation’s financial position and core operating performance. Investors sometimes use EBITDA as it allows for some level of comparability of profitability trends between those businesses differing as to capital structure and capital intensity by removing the impacts of depreciation and amortization. EBITDA also does not include changes in major working capital items such as receivables, inventory and payables, which can also indicate a significant need for, or source of, cash. Since decisions regarding capital investment and financing and changes in working capital components can have a significant impact on cash flow, EBITDA is not a good indicator of a business’s cash flows. We use EBITDA for evaluating the relative underlying performance of our core operations and for planning purposes. We calculate EBITDA by adjusting net income (loss) to exclude net interest expense, income tax expense or benefit, depreciation and amortization, thus the term “Earnings Before Interest, Taxes, Depreciation and Amortization” and the acronym “EBITDA.”

We also calculate an adjusted EBITDA, which excludes the effect of the non-cash income or expense associated with the mark-to-market adjustments, related to our June 2012 Warrants. The fair value of the June 2012 Warrants is re-measured each reporting period until the warrants are exercised or expire. Each reporting period, the change in the fair value of the June 2012 Warrants is either recognized as a non-cash expense or non-cash income. The change in the fair value of the June 2012 Warrants is not impacted by our actual operations but is instead strongly tied to the change in the market value of our common stock. Management uses adjusted EBITDA to evaluate our underlying operating performance and for planning and forecasting future business operations. We believe this adjusted EBITDA is helpful for investors to better understand our underlying business operations. The following table reconciles EBITDA and adjusted EBITDA to net income (loss) for the three and nine months ended March 31, 2016 and 2015:

|  | Three months ended: March 31, 2016 | March 31, 2015 | Nine months ended: March 31, 2016 | March 31, 2015 |
| --- | ---: | ---: | ---: | ---: |
| Net income (loss) | $775,758 | $89,791 | $1,083,148 | $(348,046) |
| Depreciation and amortization | 219,377 | 116,866 | 609,029 | 392,088 |
| Income taxes | 126,970 | 800 | 131,054 | 1,836 |
| Interest expense | 8,287 | 2,931 | 30,100 | 26,332 |
| EBITDA | 1,130,391 | 210,388 | 1,853,329 | 72,210 |
| Change in fair value of warrant liability | (661,854) | 105,518 | 25,211 | (375,308) |
| Adjusted EBITDA | $468,537 | $315,906 | $1,878,542 | $(303,098) |

30

Our adjusted EBITDA for the three months ended March 31, 2016 was approximately $469,000, compared to approximately $316,000 for the three months ended March 31, 2015. The difference in adjusted EBITDA between the periods was principally caused by higher revenue recognized in the three months ended March 31, 2016.

Our adjusted EBITDA for the nine months ended March 31, 2016 was approximately $1.88 million, compared to approximately ($303,000) for the nine months ended March 31, 2015. The difference in adjusted EBITDA between the periods was principally caused by higher revenue recognized in the nine months ended March 31, 2016.

### Off Balance Sheet Arrangements

We do not engage in any activities involving variable interest entities or off-balance sheet arrangements.

### Critical Accounting Policies and Estimates

**Allowance for accounts receivable** is calculated by taking 100% of the total of invoices that are over 90 days past due from due date and 10% of the total of invoices that are over 60 days past due from the due date for U.S. based accounts and 100% on invoices that are over 120 days past due for China based accounts without an agreed upon payment plan. Accounts receivable are customer obligations due under normal trade terms. We perform continuing credit evaluations of our customers’ financial condition. Recovery of bad debt amounts which were previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. If our actual collection experience changes, revisions to our allowance may be required. After attempts to collect a receivable have failed, the receivable is written off against the allowance.

**Inventory obsolescence reserve** is calculated by reserving 100% for items that have not been sold in two years or that have not been purchased in two years or which we have more than a two year supply. These items as identified are reserved at 100%, as well as reserving 50% for other items deemed to be slow moving within the last twelve months and reserving 25% for items deemed to have low material usage within the last six months. The parts identified are adjusted for recent order and quote activity to determine the final inventory reserve.

**Revenue** is recognized from product sales when products are shipped to the customer, provided that we have received a valid purchase order, the price is fixed, title has transferred, collection of the associated receivable is reasonably assured, and there are no remaining significant obligations. Revenues from product development agreements are recognized as milestones as completed in accordance with the terms of the agreements and upon shipment of products, reports or designs to the customer. Invoiced amounts for value-added taxes (VAT) related to sales are posted to the balance sheet and not included in revenue. Revenue recognized from equipment leasing is recognized over the lease term.

**Stock based compensation** is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. We estimate the fair value of each stock option as of the date of grant using the Black-Scholes-Merton pricing model. Most options granted under the Plan vest ratably over two to four years and generally have ten-year contract lives. The volatility rate is based on four-year historical trends in common stock closing prices and the expected term was determined based primarily on historical experience of previously outstanding options. The interest rate used is the U.S. Treasury interest rate for constant maturities. The likelihood of meeting targets for option grants that are performance based are evaluated each quarter. If it is determined that meeting the targets is probable then the compensation expense will be amortized over the remaining vesting period.

## Controls and procedures

As filed, 1,011 characters.

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of March 31, 2016, the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2016 in reporting on a timely basis information required to be disclosed by us in the reports we file or submit under the Exchange Act.

During the fiscal quarter ended March 31, 2016, there was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Filed May 5, 2016.
Source: SEC EDGAR, the filing index for accession 0001387131-16-005275. Last ingested by Listed: Nov 11, 2026, 01:28 ET. No prices; not investment advice.
